Phase
Alumni community member
Acorai
Acorai is redefining heart failure monitoring by developing a non-invasive intracardiac pressure monitor. The hardware with a four-sensor technology combined with a machine learning engine ensures superior signal quality and robustness across patient subtypes and clinical environments.
Filip founded Acorai in 2019 with the vision of transforming the treatment and management of heart failure through novel technology and applied machine learning. He has several years of experience working with Artificial Intelligence within quantitative finance in London and Switzerland and has an MA in Economics from the University of Edinburgh.
Did you know?
50% of heart failure patients require readmission within 6 months, 75% of which may be preventable.
Non-invasive cardiac pressure monitoring device
Accelerated drug development in oncology
Unique stem cell therapeutics
3D cell culture systems
Rapid Diagnostics for Multi-pathogen detection
Individualised information of the intestinal flora
Imaging solutions for life sciences
Novel probiotics for therapeutic effect
Treatments based on nature’s own defenses
Pest control solutions for bed bugs
Neonatal Lung Analyzer
Prebiotics for irritable bowel syndrome
Nanotechnology based infection control
Excellence in designing & executing drug discovery
Models for autoimmune & inflammatory conditions
Ultrasensitive cancer diagnostics & monitoring
Structural biology & drug discovery services
Male-Factor Infertility Diagnostics
Customized in vitro and in vivo services
Stroke detection device
Wound treatment gel
Regenerative medicine & cancer
